Recombinant tissue plasminogen activator (rTPA) management for first onset acute Ischemic Stroke with covid -19 and non-covid -19 patients

In this study we compare the efficacy and safety of Tissue plasminogen activator (rTPA) in acute ischemic stroke (AIS) patients with or without Covid-19 infection.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research